戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y inert drug-like and bioavailable compound (clozapine-N-oxide).
2  a concurrent gain in potency for the ligand clozapine N-oxide.
3 us administration of the inert DREADD ligand clozapine-N-oxide.
4 g intracranial or systemic administration of clozapine N-oxide (CNO) and tested the ability of system
5                               Males received clozapine N-oxide (CNO) or vehicle injections before eac
6 mporally by the administration of the ligand clozapine N-oxide (CNO).
7 exclusively activated by the "designer drug" clozapine N-oxide (CNO).
8 nergic neurons, administration of the ligand clozapine-N-oxide (CNO) by systemic injection attenuated
9                                Administering clozapine-N-oxide (CNO) enabled precise DREADD-dependent
10 coupled receptor with the synthetic compound clozapine-N-oxide (CNO) evoked a short and transient Ca(
11 d and subsequently activated by their ligand Clozapine-N-oxide (CNO) in conjunction with fear extinct
12  adora2A-rM3Ds mouse, activation of rM3Ds by clozapine-N-oxide (CNO) induces DARPP-32 phosphorylation
13 nd after administration of the DREADD ligand clozapine-N-oxide (CNO) or vehicle (saline).
14 und that activation of hM(4)D receptors with clozapine-N-oxide (CNO) potently reduced striatal neuron
15 ce expressing Gi-DREADD were normal, 1 mg/kg clozapine-N-oxide (CNO) produced a significant 3 h incre
16 er injection of saline or the hM3/hM4 ligand clozapine-N-oxide (CNO) under baseline conditions and un
17  ligand, but can be efficiently activated by clozapine-N-oxide (CNO), an otherwise pharmacologically
18                                Chemogenetic [clozapine-N-oxide (CNO)-hM4Di] perturbation of Tac1-Pet1
19 idal neurons and activated the receptor with clozapine-N-oxide (CNO).
20 tion to a bioinert drug-like small molecule, clozapine-N-oxide (CNO).
21 ons could be dose-dependently inactivated by clozapine-n-oxide (CNO).
22 lencer in the presence of its cognate ligand clozapine-N-oxide (CNO).
23 lly inactive and orally bioavailable agonist clozapine-N-oxide (CNO).
24 ated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO).
25 acologically inert, orally bioavailable drug clozapine-N-oxide (CNO).
26 ated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO).
27 d AAV-hSYN-eYFP vector that was treated with clozapine-N-oxide (CNO; 3 mg/kg, i.p.) before stage II s
28 cologically inert, but bioavailable, ligand (clozapine-N-oxide; CNO), while being non-responsive to e
29                                    Likewise, clozapine-N-oxide-induced inhibition of PV interneurons
30  otherwise pharmacologically inert compound (clozapine-N-oxide), leading to the conditional activatio
31 was later activated by systemic injection of clozapine-N-oxide, neural activity in RSC was transientl
32                 Chemogenetic activation with clozapine N-oxide resulted in delayed estrous cycles and
33 ly more potent than the parent drug, whereas clozapine N-oxide was essentially inactive.
34  M3D-arr using the otherwise inert compound, clozapine-N-oxide, we found that M3D-arr activation incr

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。